Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001465" target="_blank" >RIV/00064190:_____/25:10001465 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61383082:_____/25:00001526 RIV/00216224:14110/25:00143502 RIV/00216208:11110/25:10498424 RIV/00216208:11130/25:10498424 RIV/00064203:_____/25:10498424

Výsledek na webu

<a href="https://doi.org/10.1155/proc/1468262" target="_blank" >https://doi.org/10.1155/proc/1468262</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/proc/1468262" target="_blank" >10.1155/proc/1468262</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer

Popis výsledku v původním jazyce

Background: Abiraterone acetate is an androgen-receptor pathway inhibitor commonly used for treatment of metastatic prostate cancer. The levels of androgens during treatment with abiraterone acetate with prednisone (AAP) are lower than those achieved by androgen-deprivation therapy only, potentially resulting in a high risk of skeletal muscle loss. Methods: The cohort included 43 patients treated with AAP for metastatic hormone-sensitive prostate cancer or metastatic castration-resistant prostate cancer. To detect and quantify sarcopenia, we utilized standard computer tomography (CT) imaging. Skeletal muscle mass index (SMI) was evaluated by assessing two adjacent axial sections at the level of the L3 vertebra. Results: Sarcopenia at the time of AAP initiation was present in 72.1% of patients. Body mass index (BMI) was inversely associated with the presence of sarcopenia at the time of AAP initiation. There was a statistically significant decrease in SMI over AAP treatment. Age &gt; 75 years and the absence of previous radiotherapy were associated with a higher rate of SMI decrease during AAP therapy. Overall and progression-free survival was not significantly associated with SMI decrease during AAP therapy. Conclusions: SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy. Copyright (C) 2025 Eva Streckova et al. Prostate Cancer published by John Wiley &amp; Sons Ltd.

Název v anglickém jazyce

Skeletal Muscle Loss During Treatment With Abiraterone in Patients With Metastatic Prostate Cancer

Popis výsledku anglicky

Background: Abiraterone acetate is an androgen-receptor pathway inhibitor commonly used for treatment of metastatic prostate cancer. The levels of androgens during treatment with abiraterone acetate with prednisone (AAP) are lower than those achieved by androgen-deprivation therapy only, potentially resulting in a high risk of skeletal muscle loss. Methods: The cohort included 43 patients treated with AAP for metastatic hormone-sensitive prostate cancer or metastatic castration-resistant prostate cancer. To detect and quantify sarcopenia, we utilized standard computer tomography (CT) imaging. Skeletal muscle mass index (SMI) was evaluated by assessing two adjacent axial sections at the level of the L3 vertebra. Results: Sarcopenia at the time of AAP initiation was present in 72.1% of patients. Body mass index (BMI) was inversely associated with the presence of sarcopenia at the time of AAP initiation. There was a statistically significant decrease in SMI over AAP treatment. Age &gt; 75 years and the absence of previous radiotherapy were associated with a higher rate of SMI decrease during AAP therapy. Overall and progression-free survival was not significantly associated with SMI decrease during AAP therapy. Conclusions: SMI decline occurs during AAP treatment for mHSPC and mCRPC, and is more pronounced in patients over 75 years old and those without previous local treatment. There was no statistically significant association between survival outcomes and SMI decline during AAP therapy. Copyright (C) 2025 Eva Streckova et al. Prostate Cancer published by John Wiley &amp; Sons Ltd.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Prostate Cancer

ISSN

2090-3111

e-ISSN

—

Svazek periodika

2025

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

nestránkováno

Kód UT WoS článku

001490449800001

EID výsledku v databázi Scopus

2-s2.0-105005777804